Dexamethasone intravitreal implant for treating diabetic macular oedema

2.1 Dexamethasone 700 micrograms intravitreal implant (Ozurdex, AbbVie), is 'indicated for the treatment of adult patients with visual impairment due to diabetic macular oedema who are pseudophakic or who are considered insufficiently responsive to, or unsuitable for non-corticosteroid therapy'.

2.2 The dosage schedule is available in the summary of product characteristics for dexamethasone.

2.3 Dexamethasone intravitreal implant costs £870.00 per 700 micrograms (excluding VAT; BNF accessed online July 2022). Costs may vary in different settings because of negotiated procurement discounts.